Nicole Lamanna, MD, Associate Professor of Clinical Medicine, Columbia University Medical Center, discusses incorporating novel therapies into the standard treatment paradigm for patients with chronic lymphocytic leukemia (CLL).
Nicole Lamanna, MD
Advertisement
Nicole Lamanna, MD, is a hematologic oncologist at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irving Medical Center
Articles by Nicole Lamanna, MD
Nicole Lamanna, MD, clinical professor of medicine, Columbia University Medical Center, discusses lymphocytosis following treatment with new, oral CLL agents.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Allogeneic BCMA CAR T-Cell Therapy CT0596 Elicits 100% ORR in R/R Myeloma and Plasma Cell Leukemia
2
FDA Approves Palbociclib Plus Trastuzumab, With/Without Pertuzumab, and ET as Maintenance in HR+, HER2+ Metastatic Breast Cancer
3
NCCN Includes PCR ctDNA-MRD Testing in MIBC Treatment Algorithm
4
Tirabrutinib May Shift the R/R PCNSL Treatment Paradigm Toward Improved Tolerability
5